SEQC2 is the FDA-led community-wide Sequencing Quality Control (SEQC) consortium to develop best practices with recommended standard analysis protocols and quality control metrics for whole genome sequencing and target gene sequencing technologies that will support regulatory science research and precision medicine.
SEQC2 (Sequencing Quality Control Phase 2) primary goal is to develop standard analysis protocols and quality control metrics for fit-for-purpose use of NGS data to enhance regulatory science research and precision medicine.
With Cesare Furlanello as President-elect, MPBA is member of the Steering Committee of the MAQC Society, and we will organize “Massive Analysis and QC 2019”, hosted in Italy. Launched in 2017, the MAQC Society provides a platform for the members to address and discuss the issues related to reproducibility, QC, and statistics in dealing with the large datasets from the emerging technologies. The contribution of MPBA will be the application of DL for Precision Medicine.